SAN DIEGO, April 24, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that it will host a virtual Research & Development Day for analysts, investors and media on Tuesday, May 2, 2017, beginning at 9:00 a.m. PT. This event will be available via webcast and conference call.
The event will provide a comprehensive overview of Vical’s product pipeline with an emphasis on the HSV-2 and invasive aspergillosis programs, including presentations by members of the Vical leadership team and two leading experts:
- Anna Wald, MD, MPH, Professor, Department of Medicine, Epidemiology and Laboratory Medicine at the University of Washington and Lead Investigator in the ongoing Phase 2 trial of Vical’s HSV-2 therapeutic vaccine candidate
- Haran Schlamm, MD, infectious disease specialist and former Senior Medical Director at Pfizer, responsible for clinical development, medical and regulatory affairs for Pfizer’s antifungal portfolio
Listeners may access the accompanying slide presentation through the webcast at www.vical.com. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2239 (preferred), or (888) 455-2308 (toll-free), and reference confirmation code 9084195. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 9084195. The call also will be available live and archived through the events page at www.vical.com. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by e-mail at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Tony Ramos (858) 646-1127 Website: www.vical.com


Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 



